News & Events
2025-12-29
Pamplona Therapeutics Receives FDA Clearance of IND Application for First-in-Class IRAK4 Degrader
Pamplona Therapeutics today announced that its first-in-class targeted protein degrader for the treatment of autoimmune diseases has received clearance from the U.S. Food and Drug Administration (FDA).
Learn more
Address :
Email :
8/F, Building 1B, Weiguang Life
Science Park, Guangming District,
Shenzhen, Guangdong, China
info@pamplonatx.com
Follow us：
Follow us：
© 2025 Pamplona Therapeutics. All rights reserved.
© 2025 Pamplona Therapeutics.
All rights reserved.
All rights reserved.
